5-Year CROWN Data Show Continued Benefit With Lorlatinib in Advanced ALK-Positive NSCLC

JanineT GRACE Community Outreach
GRACE Community Outreach Team

It's exciting to see such PFS numbers for advanced NSCLC.  From ASCO Daily News, Benefit With Lorlatinib in Advanced ALK-Positive NSCLC

Key Points:

  • At 5-year follow-up, lorlatinib continues to show progression-free survival (PFS) benefit versus crizotinib in patients with previously untreated advanced ALK-positive non–small cell lung cancer (NSCLC) with no new safety signals.
  • Median PFS was not reached with lorlatinib compared with 9.1 months with crizotinib.
  • The majority of patients (92%) assigned to lorlatinib were free from intracranial progression.
I joined GRACE as a caregiver for my husband who had a Pancoast tumor, NSCLC stage III in 2009. He had curative chemo/rads then it was believed he had a recurrence in the spine/oligometastasis that was radiated. He's 10 years out from treatment.